We are developing cutting-edge cell therapies and antibody-based medicines
for the treatment of liver diseases.


35,000
people die of chronic or cirrhotic liver diseases each year in US
13,705
patients were on the waiting list for a liver transplantation in the US in 2016
7,841
liver transplants were reported in the US in 2016

At Promethera® Biosciences, we are pioneering the development of liver stem cell therapies to help patients in need of liver transplantation to restore liver health.

35,000
people die of chronic or cirrhotic liver diseases each year in US
13,705
patients were on the waiting list for a liver transplantation in the US in 2016
7,841
liver transplants were reported in the US in 2016

Our passion translates into a commitment to holistically change patients’ lives by developing liver therapies for unmet medical needs, but also by providing high quality education about liver disease and how to prevent it through healthy lifestyle choices.

We are developing groundbreaking treatments for end-stage liver disease.

HepaStem is our most advanced cell-based therapy and has the potential to deliver novel treatment options for chronic and acute liver diseases, especially for decompensated cirrhosis in late-stage such as Acute-on-Chronic Liver Failure (ACLF) and Non-Alcoholic SteatoHepatitis (NASH), as well as fibrosis.

At Promethera® Biosciences, we are striving to be the global leader in regenerative medicine and cell therapy for liver diseases.

Our broad intellectual property portfolio includes a proprietary antibody therapy, a human organ and cell sourcing, as well as outstanding manufacturing capabilities. It brings a unique set of technological assets, exclusive IP and know-how.

Restoring Liver Health

Twitter feed

Promethera provides leadership team update: Zimeng Dong, Alain Parthoens, and Etienne Sokal will form an executive committee that will collectively exercise the function of the CEO. Prof Sokal, MD, PhD, founder of Promethera has been elected as Chairman of the Board.

HepaStem is in development as an alternative to #liver transplant, which is the only option for patients with late stage #ACLF. Derived from liver stem cells, HepaStem cells migrate through the blood to the liver, where they settle and support tissue regeneration. #livertwitter

Based on promising data announced last year, we initiated a Phase 2b trial this past January to further evaluate HepaStem in #ACLF. HepaStem demonstrated a positive safety profile and a trend toward efficacy based on 3 indicators of #liver disease severity.